iBio posts $33M net loss in fiscal 2026 as R&D spending surges

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. VRNS
2. CRWV
3. TSLA
4. JBHT
5. SCHW
6. GPRK
7. AA
8. TRV
9. ABBV
10. TFC

Go back to iBio posts $33M net loss in fiscal 2026 as R&D spending surges

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

August 28, 2026 7:00 AM EDT

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.

Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition, said Martin... More